The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates is a research paper published in eLife (2021). On theSindex it has a DataRank of 0. It has been cited 62 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R35GM118047
NIAID NIH HHS
Grant: R01 AI089728
NIAID NIH HHS
Grant: R01 AI129269
NIAID NIH HHS
Grant: P01 AI060699
NIH HHS
Grant: R01AI157975
NIH HHS
Grant: S10 OD021527
NIGMS NIH HHS
Grant: P30 GM124165
National Institutes of Health
Grant: 3P30GM124165-03S1
NE-CAT: A Resource for Advanced Macromolecular Crystallography
National Science Foundation
Grant: 2029943
RAPID Enhanced SARS-CoV-2 High-Throughput Crystallization for Structural Studies
National Institutes of Health
Grant: 2R35GM118047-06
Structural studies of viral replication and invasion
National Institutes of Health
Grant: 5R01AI089728-07
Receptor recognition and cell entry of coronaviruses
National Institutes of Health
Grant: 1S10OD021527-01
Pixel Array Detector for Macromolecular Crystallography
National Institutes of Health
Grant: 7R01AI157975-02
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
University of Minnesota
Prostate Cancer Foundation
FWCI
3.59
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals